GO:0030148 sphingolipid biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030148 (sphingolipid biosynthetic process) describes the chemical reactions and pathways that build sphingolipids, a lipid class defined by a long-chain amine diol backbone such as sphingosine.
• The pathway begins with de novo condensation of serine and palmitoyl-CoA and proceeds through ceramide, the central hub metabolite that is subsequently converted into sphingomyelin and complex glycosphingolipids.
• Sphingolipids are not merely structural membrane lipids; they act as signaling molecules controlling cell growth, differentiation, apoptosis, and inflammatory responses.
• Dysregulated sphingolipid biosynthesis is implicated in cancer, metabolic disease, liver fibrosis, and drug-induced hepatotoxicity.
• Key enzymes such as SPTLC1/2, KDSR, CERS family members, DEGS1, and SGMS1/2 are attractive targets for CRISPR knockout, point-mutation, and knock-in studies.
• Studying this pathway requires integrated approaches including lipidomics, spatial lipidomics, transcriptomics, and targeted gene editing.
Description
Sphingolipids are a structurally diverse family of membrane lipids characterized by a long-chain amine diol backbone, typically sphingosine or a closely related sphingoid base. The Gene Ontology term GO:0030148, sphingolipid biosynthetic process, captures the complete set of chemical reactions and pathways that generate these molecules, from the initial condensation of serine with palmitoyl-CoA through the formation of ceramide and its downstream conversion into complex sphingolipids such as sphingomyelin and glycosphingolipids. Because sphingolipids are essential components of eukaryotic membranes and also serve as potent bioactive signaling molecules, the biosynthetic process is tightly regulated and central to cell physiology.
sphingolipid biosynthetic process At A Glance
| GO ID | GO:0030148 |
|---|---|
| GO term | sphingolipid biosynthetic process |
| Ontology | biological_process |
| Synonym | sphingolipid anabolism; sphingolipid biosynthesis; sphingolipid formation; sphingolipid synthesis |
| Major function | Synthesis of sphingolipids including ceramide, sphingomyelin, and glycosphingolipids |
| Key intermediates | Sphinganine, dihydroceramide, ceramide, sphingomyelin |
| Key enzymes | SPTLC1/2, KDSR, CERS1-6, DEGS1, SGMS1/2, UGCG |
| Cellular location | Endoplasmic reticulum and Golgi apparatus |
| Related processes | Sphingolipid catabolism, ceramide signaling, membrane lipid homeostasis |
What Is GO:0030148?
GO:0030148 (sphingolipid biosynthetic process) is defined as the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). In practical terms, it encompasses all enzymatic steps that build sphingoid bases, ceramides, and more complex sphingolipids from simple precursors.
Why Is sphingolipid biosynthetic process Important in Cell Biology?
Sphingolipid biosynthesis is fundamental to membrane integrity, lipid raft formation, and cell signaling, and its dysregulation is linked to a broad spectrum of human diseases including cancer, metabolic disorders, liver fibrosis, and drug-induced toxicity. Understanding the pathway at the molecular level is therefore critical for identifying therapeutic targets and biomarkers.
• Sphingolipids are essential structural components of eukaryotic membranes and lipid rafts.
• Ceramide, a central product of the pathway, regulates apoptosis, senescence, and stress responses.
• Altered sphingolipid metabolism is a hallmark of many cancers and contributes to chemoresistance.
• Sphingolipid biosynthesis is implicated in metabolic diseases such as obesity and insulin resistance.
• Spatial lipidomics has identified sphingolipid metabolism as an anti-fibrotic target in the liver.
• Drug-induced hepatotoxicity can arise from disturbance of cholesterol and sphingolipid metabolism.
• Sphingolipid-binding proteins mediate transport and signaling, expanding the pathway's functional reach.
• Enzymes of the pathway are druggable targets, with inhibitors in clinical trials for cancer and metabolic disease.
• Genetic defects in sphingolipid biosynthesis cause rare inherited disorders such as hereditary sensory neuropathy.
• CRISPR-based models enable causal dissection of individual enzymatic steps in the pathway.
What Happens During sphingolipid biosynthetic process?
De novo synthesis of sphingoid bases
In simple terms: The cell builds the lipid backbone by joining two simple molecules.
The first committed step is the condensation of L-serine with palmitoyl-CoA, catalyzed by serine palmitoyltransferase (SPT), a heterodimer of SPTLC1 and SPTLC2 or SPTLC3 subunits. This reaction produces 3-ketodihydrosphingosine, which is rapidly reduced to sphinganine (dihydrosphingosine) by 3-ketodihydrosphingosine reductase (KDSR).
Formation of dihydroceramide and ceramide
In simple terms: The backbone is modified with a fatty acid to create a key intermediate.
Sphinganine is N-acylated by ceramide synthases (CERS1-6), each with distinct fatty acyl chain specificity, to form dihydroceramide. Dihydroceramide desaturase (DEGS1) then introduces a double bond, converting dihydroceramide to ceramide, the central hub of sphingolipid metabolism.
Synthesis of complex sphingolipids
In simple terms: Ceramide is further decorated to make diverse sphingolipids.
Ceramide is transported from the endoplasmic reticulum to the Golgi, where it is converted to sphingomyelin by sphingomyelin synthases (SGMS1/2) or to glucosylceramide by UDP-glucose ceramide glucosyltransferase (UGCG), the entry point for glycosphingolipid synthesis. These complex sphingolipids are then delivered to membranes and participate in signaling and recognition.
Regulation of flux through the pathway
In simple terms: The cell adjusts how much sphingolipid it makes based on need.
The pathway is regulated at multiple levels, including transcriptional control of SPT and CERS genes, post-translational modification of enzymes, and feedback inhibition by downstream sphingolipids. Cellular stress, growth factors, and inflammatory signals can rapidly alter flux through the pathway.
Transport and distribution of sphingolipids
In simple terms: Newly made sphingolipids are moved to where they are needed.
Sphingolipid transport involves vesicular and non-vesicular mechanisms, with ceramide transfer protein (CERT) and other lipid transfer proteins shuttling intermediates between organelles. Sphingolipid-binding proteins further modulate their localization and function.
Key Genes Involved in GO:0030148 sphingolipid biosynthetic process
The following genes encode core enzymes and regulators of the sphingolipid biosynthetic process, and are frequently studied using CRISPR-based approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPTLC1 | Serine palmitoyltransferase subunit; first step of sphingoid base synthesis | Mutations cause hereditary sensory neuropathy; target for knockout studies |
| SPTLC2 | Serine palmitoyltransferase catalytic subunit | Key regulator of de novo sphingolipid synthesis; knockout alters ceramide levels |
| SPTLC3 | Alternative SPT subunit with distinct acyl-CoA preference | Modulates sphingolipid diversity; relevant in metabolic disease |
| KDSR | 3-ketodihydrosphingosine reductase; reduces ketone intermediate | Defects cause skin and platelet disorders; knockout models available |
| CERS1 | Ceramide synthase with preference for C18 fatty acyl chains | Linked to neurodegeneration and myopathy |
| CERS2 | Ceramide synthase for very long-chain ceramides | Implicated in cancer and metabolic disease |
| CERS4 | Ceramide synthase with broad acyl chain specificity | Potential target in liver fibrosis |
| CERS5 | Ceramide synthase for C16 ceramides | Associated with insulin resistance and inflammation |
| CERS6 | Ceramide synthase for C16 ceramides | Modulates apoptosis and cancer cell survival |
| DEGS1 | Dihydroceramide desaturase; converts dihydroceramide to ceramide | Regulates ceramide levels; knockout affects cell stress responses |
| SGMS1 | Sphingomyelin synthase; produces sphingomyelin from ceramide | Influences membrane lipid rafts and signaling |
| SGMS2 | Sphingomyelin synthase isoform | Mutations linked to skeletal disorders |
| UGCG | Glucosylceramide synthase; initiates glycosphingolipid synthesis | Target in cancer and lysosomal storage diseases |
| ASAH1 | Acid ceramidase; balances ceramide and sphingosine | Defects cause Farber disease; relevant to ceramide signaling |
| SMPD1 | Acid sphingomyelinase; hydrolyzes sphingomyelin | Deficiency causes Niemann-Pick disease |
| CERT1 | Ceramide transfer protein; transports ceramide to Golgi | Regulates sphingomyelin synthesis; knockout affects lipid homeostasis |
| ORMDL1 | Negative regulator of serine palmitoyltransferase | Modulates de novo sphingolipid synthesis; linked to asthma |
| ORMDL3 | Negative regulator of SPT; asthma susceptibility gene | Regulates sphingolipid flux; knockout increases ceramide |
How Is sphingolipid biosynthetic process Regulated?
Sphingolipid biosynthesis is regulated at transcriptional, post-translational, and metabolic levels. The serine palmitoyltransferase complex is inhibited by ORMDL proteins in response to sphingolipid levels, providing feedback control. Growth factors and stress signals modulate the expression of CERS and SGMS genes, while phosphorylation of enzymes can alter their activity. Additionally, sphingolipid transport proteins such as CERT1 determine the spatial distribution of intermediates, indirectly regulating flux through the pathway.
sphingolipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPTLC1 | Hereditary sensory neuropathy | Knock-in of patient mutations in iPSC-derived neurons |
| CERS6 | Cancer cell survival and chemoresistance | Knockout in cancer cell lines followed by drug sensitivity assays |
| UGCG | Lysosomal storage disorders and cancer | Overexpression and knockout in fibroblasts and tumor models |
| SGMS1 | Membrane signaling and cancer | Point mutation of catalytic residues in cell lines |
| CERT1 | Lipid homeostasis and liver fibrosis | Knockout in hepatocyte-like cells and organoids |
Sphingolipid biosynthesis in cancer
Altered sphingolipid metabolism is a common feature of many cancers, where shifts in ceramide and sphingosine-1-phosphate balance promote cell survival, proliferation, and chemoresistance. Targeting enzymes such as CERS6, UGCG, or SGMS1 has shown promise in preclinical models, and CRISPR knockout of these genes can reverse malignant phenotypes.
Metabolic and liver disease
Sphingolipid biosynthesis contributes to obesity, insulin resistance, and non-alcoholic steatohepatitis. Spatial lipidomics has revealed that sphingolipid metabolism is a key anti-fibrotic target in the liver, with specific ceramide species driving fibrogenesis. Disturbances in cholesterol and sphingolipid metabolism also underlie drug-induced hepatotoxicity, as seen with crizotinib.
Neurodegeneration and rare disorders
Mutations in SPTLC1, SPTLC2, and KDSR cause hereditary sensory and autonomic neuropathies, while defects in CERS1 are linked to neurodegeneration. These monogenic disorders highlight the importance of precise regulation of sphingolipid biosynthesis for neuronal survival.
From sphingolipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SPTLC2 reduce de novo sphingolipid synthesis? | CRISPR knockout in HEK293 or HepG2 cells |
| How does a patient mutation in SPTLC1 affect enzyme activity? | Point mutation knock-in in iPSCs followed by lipidomics |
| Can overexpression of CERS6 increase C16-ceramide and alter apoptosis? | Overexpression in cancer cell lines |
| What is the subcellular localization of DEGS1? | Tagged knock-in with fluorescent protein in HeLa cells |
| Does knockout of UGCG sensitize cancer cells to chemotherapy? | CRISPR knockout in tumor cell lines and xenografts |
| How does CERT1 knockout affect sphingomyelin synthesis? | Knockout in HeLa or COS-7 cells with lipid mass spectrometry |
How to Study the sphingolipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS lipidomics | Sphingolipid species and abundance | Quantifying ceramide and sphingomyelin after gene knockout |
| Spatial lipidomics | Lipid distribution in tissue sections | Identifying anti-fibrotic targets in liver |
| RNA-seq | Transcript levels of sphingolipid genes | Assessing compensatory changes after CRISPR editing |
| Proteomics | Protein expression and modifications | Validating knockout efficiency and pathway rewiring |
| Fluorescence microscopy | Subcellular localization of enzymes | Tracking CERT1 and ceramide transport |
| CRISPR screening | Gene essentiality and pathway dependencies | Identifying synthetic lethal interactions in cancer |
| Metabolic flux analysis | Rate of sphingolipid synthesis | Measuring de novo synthesis with labeled precursors |
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics is the gold standard for quantifying sphingolipid species. It can measure ceramides, sphingomyelins, and glycosphingolipids in cells and tissues, revealing how genetic perturbations alter flux through the pathway.
Spatial lipidomics
Spatial lipidomics combines imaging and mass spectrometry to map lipid distribution within tissues. This approach identified sphingolipid metabolism as an anti-fibrotic target in the liver, demonstrating its utility for discovering disease-relevant pathways.
Transcriptomics and proteomics
RNA-seq and quantitative proteomics can assess expression changes in sphingolipid enzymes after CRISPR editing. These methods help identify compensatory mechanisms and regulatory networks controlling the pathway.
Fluorescent labeling and imaging
Fluorescent sphingolipid analogs and tagged enzymes enable live-cell imaging of sphingolipid trafficking and enzyme localization. This is valuable for studying transport proteins like CERT1 and the Golgi-to-membrane delivery of complex sphingolipids.
How CRISPR Can Be Used to Study GO:0030148 sphingolipid biosynthetic process
Knockout
CRISPR knockout of core sphingolipid biosynthetic genes such as SPTLC2, CERS6, or UGCG is used to abolish enzyme activity and assess downstream effects on ceramide levels, cell viability, and drug sensitivity. Knockout cell lines serve as clean models to study the pathway's role in disease.
Point Mutation
Point mutations identified in patients, such as those in SPTLC1 or KDSR, can be introduced into cell lines or iPSCs using CRISPR base editing or homology-directed repair. These models help determine whether a specific mutation is causative or a benign variant.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous loci (e.g., DEGS1-GFP) allows real-time tracking of enzyme localization and interaction partners without overexpression artifacts. This is particularly useful for studying membrane-associated enzymes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like CERS6 or SGMS1 can elevate specific sphingolipid species, enabling gain-of-function studies to test their role in proliferation, apoptosis, and signaling.
How EDITGENE Supports sphingolipid biosynthetic process Research
Researchers studying sphingolipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype or merely correlated with it. This requires precise genetic models that can isolate the contribution of individual enzymes and mutations.
Contact EDITGENE today to design your custom CRISPR model for sphingolipid biosynthetic process research.
Frequently Asked Questions About sphingolipid biosynthetic process
What is GO:0030148 sphingolipid biosynthetic process?
GO:0030148 is a Gene Ontology biological process term describing the chemical reactions and pathways that produce sphingolipids, a class of lipids containing a long-chain amine diol backbone such as sphingosine.
What genes are involved in sphingolipid biosynthetic process?
Key genes include SPTLC1, SPTLC2, SPTLC3, KDSR, CERS1-6, DEGS1, SGMS1, SGMS2, UGCG, and CERT1, which encode enzymes catalyzing successive steps of the pathway.
Why is sphingolipid biosynthesis important in cancer?
Altered sphingolipid metabolism promotes cancer cell survival and chemoresistance, making pathway enzymes attractive therapeutic targets.
How can CRISPR be used to study sphingolipid biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to manipulate specific genes and observe effects on sphingolipid levels and cell behavior.
What diseases are linked to defects in sphingolipid biosynthesis?
Mutations in SPTLC1, SPTLC2, and KDSR cause hereditary sensory neuropathies, while dysregulated sphingolipid metabolism is implicated in cancer, metabolic disease, and liver fibrosis.
What is the central intermediate in sphingolipid biosynthesis?
Ceramide is the central hub metabolite, from which sphingomyelin and glycosphingolipids are synthesized.
Where in the cell does sphingolipid biosynthesis occur?
The pathway begins in the endoplasmic reticulum and continues in the Golgi apparatus, with transport proteins moving intermediates between compartments.
How is sphingolipid biosynthesis regulated?
It is regulated by feedback inhibition via ORMDL proteins, transcriptional control of enzymes, and post-translational modifications in response to cellular signals.
What methods are used to study sphingolipid biosynthesis?
Lipidomics, spatial lipidomics, transcriptomics, proteomics, and fluorescent imaging are commonly used to measure sphingolipid species and enzyme localization.
Can sphingolipid biosynthesis be targeted therapeutically?
Yes, inhibitors of enzymes such as SPT and UGCG are in clinical development for cancer and metabolic disorders, and CRISPR models help validate these targets.
Conclusion
GO:0030148 (sphingolipid biosynthetic process) encompasses a vital metabolic pathway that produces structural and signaling lipids essential for cell function. Its dysregulation is linked to cancer, metabolic disease, liver fibrosis, and rare neuropathies, making it a rich area for therapeutic discovery. CRISPR-based models, combined with advanced lipidomics and bioinformatics, provide powerful tools to dissect the pathway and identify new drug targets.
References
- 1. Kuo A et al.. 2024. Regulation of cellular and systemic sphingolipid homeostasis.. Nat Rev Mol Cell Biol 25(10):802-821 PMID: 38890457
- 2. Hannun YA et al.. 2018. Sphingolipids and their metabolism in physiology and disease.. Nat Rev Mol Cell Biol 19(3):175-191 PMID: 29165427
- 3. Gruevska A et al.. 2025. Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver.. Metabolism 168:156237 PMID: 40127860
- 4. Green CD et al.. 2021. Sphingolipids in metabolic disease: The good, the bad, and the unknown.. Cell Metab 33(7):1293-1306 PMID: 34233172
- 5. Gault CR et al.. 2010. An overview of sphingolipid metabolism: from synthesis to breakdown.. Adv Exp Med Biol 688:1-23 PMID: 20919643
- 6. Snook CF et al.. 2006. Sphingolipid-binding proteins.. Biochim Biophys Acta 1761(8):927-46 PMID: 16901751
- 7. Yan H et al.. 2025. Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity.. Adv Sci (Weinh) 12(14):e2414923 PMID: 39836491
- 8. Riboni L et al.. 2010. Sphingolipid transport.. Adv Exp Med Biol 688:24-45 PMID: 20919644
